Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Active-controlled Study to Assess the Safety and Efficacy of ANG003 at Two Different Dose Levels in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT07450547 is registered in ClinicalTrials.gov with Anagram Therapeutics, Inc. as lead sponsor.

NCT NCT07450547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07450547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Active-controlled Study to Assess the Safety and Efficacy of ANG003 at Two Different Dose Levels in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Lead sponsor
Anagram Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
April 24, 2026
Completion date
July 31, 2027
Enrollment
113 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis (cf), exocrine pancreatic insufficiency (epi)